Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 1/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
| ▸ | VCP | P55072 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TOP2A | P11388 | 2/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.56 |
| ▸ | FDPS | P14324 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128281 | 1.00 | JUN (0.78) | JUNNFKB1VCPALDH1A1KDM4E | |
| SCHEMBL7017036 | 0.92 | JUN (0.66) | JUNNFKB1VCPALDH1A1KDM4E | |
| SCHEMBL5934912 | 0.92 | JUN (0.66) | JUNNFKB1VCPALDH1A1KDM4E | |
| SCHEMBL29503043 | 0.89 | KDM4E (0.73) | JUNNFKB1ALDH1A1KDM4EHPGD | |
| SCHEMBL1589619 | 0.89 | KDM4E (0.73) | JUNNFKB1ALDH1A1KDM4EHPGD | |
| SCHEMBL1589618 | 0.89 | KDM4E (0.73) | JUNNFKB1ALDH1A1KDM4EHPGD | |
| SCHEMBL3207347 | 0.88 | NFKB1 (1.00) | JUNNFKB1VCPALDH1A1KDM4E | |
| SCHEMBL3207352 | 0.88 | NFKB1 (1.00) | JUNNFKB1VCPALDH1A1KDM4E | |
| SCHEMBL3674227 | 0.88 | JUN (0.82) | JUNNFKB1VCPALDH1A1KDM4E | |
| SCHEMBL3674230 | 0.88 | JUN (0.82) | JUNNFKB1VCPALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5148202-A | — | — | None | — | — | JP | disclosed |
| CN-111153898-B | Thiourea derivative and preparation method and application thereof | 南华大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-111153898-A | Thiourea derivative and preparation method and application thereof | 南华大学 | 2020-05-15 | — | — | CN | disclosed |
| US-9067908-B2 | Polyphenolic bioprecursors | RHODIA CHIMIE (FR) | 2015-06-30 | — | — | US | disclosed |
| WO-2013130020-A1 | QUERCETIN DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE | ÚSTAV EXPERIMENTÁLNEJ FARMAKOLÓGIE A TOXIKOLÓGIE SAV (SK) | 2013-09-06 | — | — | WO | disclosed |
| US-7629368-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2009-12-08 | — | — | US | disclosed |
| US-20090215881-A1 | Polyphenolic Bioprecursors | CHIMIE, Rhodia Chime (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2009-03-19 | — | — | US | disclosed |
| US-7465803-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2008-08-14 | — | — | US | disclosed |
| EP-0700908-A1 | 1-Arylpyrimidine derivatives and pharmaceutical use thereof | JAPAN ENERGY CORPORATION (JP) | 1996-03-13 | — | — | EP | disclosed |
| US-5344845-A | Methyl 4(4-acetoxy-3-methoxycinnamanide and salts as an immunosuppressive drug for allergic reactions | TSUMURA & CO. (JP) | 1994-09-06 | — | — | US | disclosed |
| JP-H05148202-A | NEW COMPOUND AND ITS USAGE AS MEDICAL DRUG | TSUMURA & CO | 1993-06-15 | — | — | JP | disclosed |
| EP-0535250-A1 | NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE | TSUMURA & CO. (JP) | 1993-04-07 | — | — | EP | disclosed |
| EP-0174064-B1 | COMPOSITIONS AND COMPOUNDS FOR THE TREATMENT OF PROSTATIC ADENOMA | INVERNI DELLA BEFFA S.P.A. (IT) | 1989-12-06 | — | — | EP | disclosed |
| US-4709076-A | UROGENITAL DISORDERS | INVERNI DELLA BEFFA SPA (IT) | 1987-11-24 | — | — | US | disclosed |
| EP-0227431-A1 | Heterocyclic amides | BEECHAM GROUP PLC (GB) | 1987-07-01 | — | — | EP | disclosed |
| EP-0174064-A2 | Compositions and compounds for the treatment of prostatic adenoma | INVERNI DELLA BEFFA S.P.A. (IT) | 1986-03-12 | — | — | EP | disclosed |
| US-4038414-A | ANTIARRHYTHMIA AGENTS | CIBA-GEIGY CORPORATION (US) | 1977-07-26 | — | — | US | disclosed |
| US-4014920-A | N-cinnamylcarbamic acid esters | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR0B1, NOX1 | JUN 4254/4885NFKB1 326/4885VCP 3674/4885 |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR2E1, CYP2E1 | JUN 4082/4885NFKB1 458/4885VCP 4195/4885 |
| US-20090215881-A1 | Polyphenolic Bioprecursors | PPARG, PPARA, FABP4 | JUN 1057/4885NFKB1 435/4885VCP 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.